Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo

Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo

Abstract Extracorporeal shock wave therapy (ESWT) has been shown to improve symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS); however, there is a lack of objective evidence. We measured change of urinary biomarker levels in 25 patients with IC/BPS received ESWT or place...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yuan-Chi Shen, Pradeep Tyagi, Wei-Chia Lee, Michael Chancellor, Yao-Chi Chuang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/d73d1d0df4e34855b3388a1dc60855fc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d73d1d0df4e34855b3388a1dc60855fc
record_format dspace
spelling oai:doaj.org-article:d73d1d0df4e34855b3388a1dc60855fc2021-12-02T14:15:53ZImproves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo10.1038/s41598-021-87040-12045-2322https://doaj.org/article/d73d1d0df4e34855b3388a1dc60855fc2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87040-1https://doaj.org/toc/2045-2322Abstract Extracorporeal shock wave therapy (ESWT) has been shown to improve symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS); however, there is a lack of objective evidence. We measured change of urinary biomarker levels in 25 patients with IC/BPS received ESWT or placebo once a week for 4 weeks. Urines were collected from participants at baseline, 4 and 12 weeks post treatment. A representative 41 inflammatory growth factors, cytokines, and chemokines in urine were measured using a MILLIPLEX immunoassay kit. Symptom bother was assessed by O’Leary-Sant symptom scores (OSS), and visual analog scale (VAS) for pain. The ESWT group exhibited a significant reduction in the OSS and VAS compared to the placebo group 4 weeks post-treatment (P < 0.05), and the effects were persistent at 12 weeks. The difference in urinary markers change in ESWT versus placebo was P = 0.054 for IL4, P = 0.013 for VEGF, and P = 0.039 for IL9 at 4 weeks. The change of urine biomarker was not significant in other biomarkers or all the measured proteins at 12 weeks. The current data suggest that IL4, IL9, and VEGF mediation may be involved in its pathophysiologic mechanisms and response to LESW treatment.Yuan-Chi ShenPradeep TyagiWei-Chia LeeMichael ChancellorYao-Chi ChuangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yuan-Chi Shen
Pradeep Tyagi
Wei-Chia Lee
Michael Chancellor
Yao-Chi Chuang
Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
description Abstract Extracorporeal shock wave therapy (ESWT) has been shown to improve symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS); however, there is a lack of objective evidence. We measured change of urinary biomarker levels in 25 patients with IC/BPS received ESWT or placebo once a week for 4 weeks. Urines were collected from participants at baseline, 4 and 12 weeks post treatment. A representative 41 inflammatory growth factors, cytokines, and chemokines in urine were measured using a MILLIPLEX immunoassay kit. Symptom bother was assessed by O’Leary-Sant symptom scores (OSS), and visual analog scale (VAS) for pain. The ESWT group exhibited a significant reduction in the OSS and VAS compared to the placebo group 4 weeks post-treatment (P < 0.05), and the effects were persistent at 12 weeks. The difference in urinary markers change in ESWT versus placebo was P = 0.054 for IL4, P = 0.013 for VEGF, and P = 0.039 for IL9 at 4 weeks. The change of urine biomarker was not significant in other biomarkers or all the measured proteins at 12 weeks. The current data suggest that IL4, IL9, and VEGF mediation may be involved in its pathophysiologic mechanisms and response to LESW treatment.
format article
author Yuan-Chi Shen
Pradeep Tyagi
Wei-Chia Lee
Michael Chancellor
Yao-Chi Chuang
author_facet Yuan-Chi Shen
Pradeep Tyagi
Wei-Chia Lee
Michael Chancellor
Yao-Chi Chuang
author_sort Yuan-Chi Shen
title Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
title_short Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
title_full Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
title_fullStr Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
title_full_unstemmed Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
title_sort improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/d73d1d0df4e34855b3388a1dc60855fc
work_keys_str_mv AT yuanchishen improvessymptomsandurinarybiomarkersinrefractoryinterstitialcystitisbladderpainsyndromepatientsrandomizedtoextracorporealshockwavetherapyversusplacebo
AT pradeeptyagi improvessymptomsandurinarybiomarkersinrefractoryinterstitialcystitisbladderpainsyndromepatientsrandomizedtoextracorporealshockwavetherapyversusplacebo
AT weichialee improvessymptomsandurinarybiomarkersinrefractoryinterstitialcystitisbladderpainsyndromepatientsrandomizedtoextracorporealshockwavetherapyversusplacebo
AT michaelchancellor improvessymptomsandurinarybiomarkersinrefractoryinterstitialcystitisbladderpainsyndromepatientsrandomizedtoextracorporealshockwavetherapyversusplacebo
AT yaochichuang improvessymptomsandurinarybiomarkersinrefractoryinterstitialcystitisbladderpainsyndromepatientsrandomizedtoextracorporealshockwavetherapyversusplacebo
_version_ 1718391751724498944

Ejemplares similares